Adverse Drug Reactions of Different Brands of Ceftazidime Injection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00173901|
Recruitment Status : Unknown
Verified January 2001 by National Taiwan University Hospital.
Recruitment status was: Active, not recruiting
First Posted : September 15, 2005
Last Update Posted : September 15, 2005
|Condition or disease||Intervention/treatment||Phase|
|Infection||Drug: ceftazidime||Phase 4|
Ceftazidime is a third generation cephalosporins that should be reserved for severe bacterial infections. Substitution of the brand ceftazidime with a generic ceftazidime raised some concerns.
The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||536 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Adverse Drug Reactions of Different Brands of Ceftazidime Injection|
|Study Start Date :||March 2001|
|Study Completion Date :||April 2002|
- The adverse drug reactions of ceftazidime
- The effectiveness of ceftazidime
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00173901
|National Taiwan University Hospital|
|Taipei, Taiwan, 100|
|Study Chair:||Shan-Chwen Chang, MD PhD||National Taiwan University Hospital|